Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Tax Provisions (2017 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Tax Provisions for 11 consecutive years, with $103.2 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 6612.74% to $103.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.9 million through Dec 2025, up 2144.27% year-over-year, with the annual reading at $81.8 million for FY2025, 2134.99% up from the prior year.
  • Tax Provisions hit $103.2 million in Q4 2025 for Vanda Pharmaceuticals, up from -$5.8 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $103.2 million in Q4 2025 to a low of -$7.9 million in Q1 2025.
  • Historically, Tax Provisions has averaged $4.8 million across 5 years, with a median of $915000.0 in 2023.
  • Biggest YoY gain for Tax Provisions was 6612.74% in 2025; the steepest drop was 1474.8% in 2025.
  • Year by year, Tax Provisions stood at $1.5 million in 2021, then skyrocketed by 80.22% to $2.7 million in 2022, then crashed by 73.21% to $730000.0 in 2023, then plummeted by 317.12% to -$1.6 million in 2024, then soared by 6612.74% to $103.2 million in 2025.
  • Business Quant data shows Tax Provisions for VNDA at $103.2 million in Q4 2025, -$5.8 million in Q3 2025, and -$7.7 million in Q2 2025.